Identify patients who are at high risk of antibody-mediated rejection
The detection of anti-human leukocyte antigen (HLA) antibodies, particularly those directed at the HLAs of the donor, has been at the forefront of donor-recipient histocompatibility testing since transplantation became a clinical reality.
Patients can form HLA antibodies in response to pregnancy and transfusion, and also in response to transplant-mismatched antigens. When they form as a result of transplant, they are commonly referred to as donor-specific antibodies (DSAs). The association of de novo DSA with subsequent graft loss suggests that screening for DSA post-transplant and early intervention could improve graft outcomes.
In recent years, literature suggests that the presence of autoantibodies may also have a potential long-term detrimental impact. The proven reliability of our single antigen bead products provide you consistency, high sensitivity and robustness for all you antibody monitoring needs.
In recent years, the literature has shown the importance of detecting and monitoring for the development of DSA with enhanced sensitivity after transplantation. In a pooled analysis of retrospective cohort studies, the presence of DSA detected by solid-phase assay, even with a negative flow cross-match, demonstrated statistical significance for increased risk for biopsy-proven antibody-mediated rejection (ABMR) and graft failure.1
LABScreen Single Antigen assays, which are used for both pre- and post-transplant applications, leverage Luminex® bead-based multiplexing technology for monitoring DSA in high-PRA patients. This highly sensitive single antigen bead-based assay identifies antibodies against HLA and is a crucial component of a complete patient management system.
In a recent study, both clinical and subclinical de novo DSA (dnDSA) were associated with an increase in graft loss. In the subclinical dnDSA group graft loss was delayed. The authors concluded that the association of dnDSA with subsequent graft loss suggests that screening for DSA post-transplant and early intervention could improve graft outcomes.
Wiebe C, et al. Am J Transplant, 2015
| Available Solutions
Interpret test results on our HLA Fusion™ Software with powerful analysis modules specifically designed to work with One Lambda molecular and antibody screening products.
| About the Assays
In high PRA patients, antibodies that are reactive to one or more dominant epitopes can mask the presence of additional antibody specificities. Conventional methods may not be effective in these cases. With LABScreen Single Antigen you can screen HLA Class I and Class II antibodies that are reactive to one or more dominant epitopes, providing a comprehensive assay for clinicians to evaluate antigens found frequently in the population.
R-PE Conjugated Anti-lgG
Mounting research suggests the importance of testing autoantibodies.2,3 LABScreen Autoantibody assays provide a convenient way to detect and monitor a broad range of autoantibody targets in human sera, using single antigen bead technology:
LABScreen Autoantibody assays follow the same workflow as LABScreen Single Antigen; they can be easily integrated into your laboratory workflow without the need for new instrumentation or extensive retraining.
For Research Use Only. Not for use in diagnostic procedures.